tbuckley/cabot-search huggingface dataset:
A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.
Authors: Richard Francis Dunne, Nicholas A. Ullman, Brian A. Belt, Luis I. Ruffolo, Paul Burchard, Aram F Hezel, Jason Zittel, Wenjia Wang, Erika E. Ramsdale, Vivek Kaul, John Zebala, David Linehan
Journal: Journal of Clinical Oncology (2022)

TPS631 Background: Survival outcomes for advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal despite improvements in systemic therapy regimens developed over the past decade. In addition, current first-line therapies result in cumulative cytopenias and neuropathy, highlighting the need for more effective, less toxic maintenance treatment strategies. There are currently no standard approved maintenance treatments for patients with PDAC not associated with BRCA or DNA-repair mutations. Pre-clinical data suggest a potential synergistic effect of combining blockade of CXC chemokine receptors (CXCR) with immunotherapy or chemotherapy in pancreatic cancer 1,2 . We are currently conducting a Phase I study (NCT04477343) evaluating SX-682, an oral CXCR1/2 inhibitor, and Nivolumab as maintenance treatment for advanced PDAC. Methods: This is an open-label, dose escalation Phase I clinical trial evaluating the combination of SX-682 and Nivolumab. Patients must have histologically confirmed unresectable PDAC and have completed at least 16 weeks of first-line chemotherapy with disease stability or treatment response at time of enrollment. Radiographically measurable disease must be present per iRECIST criteria. Patients receive a 3-week run-in phase of twice-daily dosing of SX-682, followed by combination of twice-daily dosed SX-682 and every 2-week Nivolumab (240 mg IV). Dose finding of SX-682 is performed using Bayesian optimal interval (BOIN) design to determine the maximum tolerated dose (MTD) when combined with Nivolumab. Pre-treatment and one on treatment (Day 28-35) biopsies are required for enrollment to evaluate change in tumor microenvironment immune cell composition by single cell-RNA sequencing, flow cytometry, RNA RT-qPCR, and IHC. The primary endpoint is to determine MTD; the key secondary endpoint is progression-free survival (PFS), defined as the time from enrollment to progression via iRECIST criteria or death. Nine of a planned 20 patients have been enrolled. Dose-level 1 (SX-682 50 mg BID) completed enrollment without dose-limiting toxicity (DLT). Dose-level 2, which commenced in June 2021, (SX-682 100 mg BID) is without DLTs, but has not completed enrollment at time of abstract submission. Nywening TM, Belt BA, Cullinan DR, et al. Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. 1) Gut. 2018;67(6):1112-1123. Steele CW, Karim SA, Leach JDG, et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. 2) Cancer Cell. 2016;29(6):832-845. Clinical trial information: NCT04477343.
银屑病治疗是否会增加新冠肺炎感染导致的住院或死亡风险?
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Penso et al. Br J Dermatol 2022; 186:59–68. 在新冠肺炎疫情期间, 治疗银屑病患者的医生面临的困难之一是, 要不要继续使用可能降低患者对感染的抵抗力的治疗。在这项法国研究中, 研究团队比较了接受不同类型银屑病治疗的银屑病患者与未接受治疗的银屑病患者入院和死亡的风险 (几率) 。 研究的药物包括外用药物 (即涂抹于皮肤的药物) 、口服药物和生物药物; 后两组的药物会降低某些方面的免疫应答。该团队使用来自法国国家健康数据系统中登记银屑病患者的信息, 这是一个涵盖法国全国人口 (6700 万人) 的数据库。 团队核查了两个时间段的数据, 涵盖法国的两波新冠肺炎大流行时期: 2020 年 2 月 15 日至 6 月 30 日和 2020 年 10 月 1 日至 2021 年 1 月 31 日。他们使用了来自 130 万名银屑病患者的信息; 在第一个研究时段, 3871 名患者因新冠肺炎住院, 759 (20%) 名患者死亡; 在第二个时段, 3603 名患者因新冠肺炎住院, 686 (19%) 名患者死亡。 尽管在第一时段使用外用和非生物治疗以及在第二时段使用任何治疗均与住院风险增加相关, 但在任一时段, 任何治疗组均未出现死亡风险增加。这些结果表明, 在疫情期间, 应继续对银屑病患者进行全身治疗。 Linked Article: Penso et al. Br J Dermatol 2022; 186:59–68.
Correction: Curriculum for small-bowel capsule endoscopy and device-assisted enteroscopy training in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement
Authors: Reena Sidhu, Stefania Chetcuti Zammit, Peter Baltes, Cristina Carretero, Edward J. Despott, Alberto Murino, Xavier Dray, David S. Sanders, Martin Keuchel, Evelien Dekker, James E. East, Gavin Johnson, Pedro Pimentel-Nunes, Marianna Arvanitakis, Thierry Ponchon, Mario Dinis-Ribeiro, Raf Bisschops
Journal: Endoscopy (2020)

Correction to:Curriculum for small-bowel capsule endoscopy and device-assisted enteroscopy training in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position StatementEndoscopy 2020; 52(08): 669-686DOI: 10.1055/a-1185-1289
Care home staff and residents on the pandemic front line
Authors: None The Lancet Healthy Longevity
Journal: The Lancet Healthy Longevity (2020)

On Oct 20, 2020, the Andbe care home in Norton County (KS, USA) made international headlines when a single case of COVID-19 infection spread to all 62 residents and some staff members within two weeks, resulting in ten deaths and one admission to hospital. Although this case is remarkable for the speed at which the infection spread, sadly it is not an outlier: as of September, 2020, 41% of all COVID-19 deaths in the USA occurred in nursing home facilities. Nor is this trend unique to the USA. Across 21 countries in Europe, Asia, North America, and Oceania almost half (48%) of all COVID-19 deaths have occurred in care homes.
Evaluation of efficacy and tolerance of radical radiotherapy and radiochemotherapy in treatment of locally advanced, unresectable rectal cancer.
Authors: Małgorzata Kraszkiewicz, Aleksandra Napieralska, Jerzy Wydmanski, Wojciech Majewski
Journal: Journal of Clinical Oncology (2022)

133 Background: Evaluation of tolerance and efficacy of two schemes of neoadjuvant treatment in patients with unresectable rectal cancer: radiochemotherapy and radiotherapy, including conventional and accelerated hyperfractionation. Methods: 145 patients (pts) with unresectable, locally advanced rectal cancer. Schemes used: radiotherapy (RT) in 73 (50%) or radiochemotherapy (CRT) in 72 (50%). In RT group conventional fractionation (CFRT) and hyperfractionated accelerated radiotherapy (HART). In CRT 54 Gy in 1.8 Gy fractions was given with two cycles of 5 Fu-LV chemotherapy in three or five day cycles. Results: Objective response (OR) in RT and CRT group was 60% versus 75%. Resection rate (RR) in RT and CRT: 37% versus 65%. Tumor mobility and laparotomy-based unresectability were significant factors for OR. Performance status, tumor mobility, neoadjuvant treatment method were significant for RR. Five-year LC in CRT versus RT: 68% versus 37%. Five-year OS: 52% versus 27%. CRT was independent positive prognostic factor for resection rate, local control. Tumor volume did not reach significance for any of the end points. Lenght of chemotherapy cycles (three or five days) did not reach significance for any of the endpoints. Toxicity was acceptable in both groups. CRT had best outcome in LC: 68% versus 42% in HART; and 25% in CFRT. Five-year OS was much better in CRT than in CFRT: 52% versus 17%. Conclusions: The results of treatment depend on performance status, patients age, tumor mobility and unresectability based on earlier laparotomy. The lack of influence of the tumor volume on all endpoints indicates the need for radical neoadjuvant treatment independently of tumor volume and underlines the key role of a proper surgical treatment. In patients not suitable for CRT, HART is optimal strategy for its better efficacy than CFRT.
Increased DNA content and transcriptional activity in myocytes from pressure overloaded human myocardium Eyal Arnon, Stefan Hein, Sawa Kostin, Manfred Richter, Erwin P. Bauer, Wolf P. Kl�vekorn, Jutta Schaper. Max-Planck-Institute, Bad Nauheim, Germany, Kerckhoff-Clinik, Bad Nauheim, Germany
Journal: Journal of the American College of Cardiology (2001)
PEKING, CHINA
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC
Authors: Sun Min Lim, Chang Gon Kim, Jii Bum Lee, Byoung Chul Cho
Journal: Cancer Discovery (2022)

Abstract Summary: HER3 is ubiquitously expressed in EGFR-mutant non–small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC. See related article by Jänne et al., p. 74.
Primary angioplasty in the elderly: Predictors of angiographic and clinical outcome in the era of stents and IIb/IIIa inhibitors Satyendra Giri, Jeffrey A. Hirst, Francis J. Kiernan, Daniel B. Fram, Jeffrey J. Popma, Charles A. Primiano, Joseph Mitchel. Brigham &amp; Women's Hospital, Boston, MA, Hartford Hospital, Hartford, CT
Journal: Journal of the American College of Cardiology (2001)
Table of Contents
Authors: A Passaro, S Peters, T Mok, I Attili, T Mitsudomi, F De Marinis, M Pavel, K Öberg, M Falconi, E Krenning, A Sundin, A Perren, A Berruti, T Yoshino, G Pentheroudakis, S Mishima, M Overman, K.-H Yeh, E Baba, Y Naito, F Calvo, A Saxena, L.-T Chen, M Takeda, A Cervantes, H Taniguchi, K Yoshida, Y Kodera, Y Kitagawa, J Tabernero, H Burris, J.-Y Douillard, V Dunnett-Kane, E Burkitt-Wright, F Blackhall, A Malliri, D Evans, C Lindsay, C Bailey, M Shoura, P Mischel, C Swanton, L Zhang, F Zhu, L Xie, C Wang, J Wang, R Chen, P Jia, H Guan, L Peng, Y Chen, P Peng, P Zhang, Q Chu, Q Shen, Y Wang, S Xu, J Zhao, M Zhou, J Shim, H Kim, H Cha, S Kim, T Kim, V Anagnostou, Y.-L Choi, H Jung, J.-M Sun, J Ahn, M.-J Ahn, K Park, W.-Y Park, S.-H Lee
Journal: Annals of Oncology (2020)
Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
Authors: Zhongzheng Lu, Yanli Jin, Chun Chen, Juan Li, Qi Cao, Jingxuan Pan
Journal: Molecular Cancer (2021)

An amendment to this paper has been published and can be accessed via the original article.
The Lettsomian Lectures being Practical Observations on Cancer of the Breast: Delivered before the Medical Society of London, April 2nd, 1900
Authors: W. Banks
Journal: BMJ (1900)

IT would be out of place here to enter into a detailed history of the early searchings after truth in this matter, for, how- ever praiseworthy, nothing definite came of them.The first notable step in advance was made by Dr. Russell, of Edin- burgh, in I890.In the BRITISH MEDICAL JOURNAL for De- cember of that year will be found a paper by him modestly entitled " A Characteristic Organism of Cancer."Seeing that they were well displayed by staining with fuchsin, he termed them " fuchsin bodies."The attaching of men's names to all sorts of silly little discoveries and operations is much to be deprecated, but so important a move in the right rdirection might well be commemorated by designating them Russell's bodies.He described them both as intracellular and extra- cellular, and, what is of much importance, he held them to be blastomycetes, a variety of the saccharomycetes or yeasts.The general opinion was distinctly against him, but in the Annals de l'Institut Pasteurfor 1890 appeared a paper by Pro- fessor Soudakewitch of Kieff, " Parasitisme Intracellulaire des Neoplasies Canc6reuses," describing and figuring bodies obvi- ously very similar to Russell's bodies, and in the same year (.Tournal of Pathology) a very important contribution by Armand Ruffer containing confirmatory evidence.Preparations illustrating both these papers were shown to Metchni- koff, and that distinguished pathologist gave it as his opinion that the bodies were "parasitic protozoa."This at once altered the venue from the vegetable to the animal kingdom.In this country the fuller investigation of the parasite has been very ably carried on by Mr. Plimmer, of St. Mary's Hospital.In the so-called Cancer Number of the Pr actitioner, already referred to, will be found a review by him of the whole question up to April, I899.It is a model of clear unbiassed writing, and the description of the general structure of cancer and methods of examination most admirable.20. A. R.
Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
Authors: Alexi Vasbinder, Elizabeth Anderson, Husam Shadid, Hanna Berlin, Michael Pan, Tariq U. Azam, Ibrahim Khaleel, Kishan Padalia, Chelsea Meloche, Patrick O’Hayer, Erinleigh Michaud, Tonimarie Catalan, Rafey Feroze, Pennelope Blakely, Christopher Launius, Yiyuan Huang, Lili Zhao, Lynn Ang, Monica Mikhael, Kara Mizokami-Stout, Subramaniam Pennathur, Matthias Kretzler, Sven H. Loosen, Athanasios Chalkias, Frank Tacke, Evangelos J. Giamarellos-Bourboulis, Jochen Reiser, Jesper Eugen-Olsen, Eva L. Feldman, Rodica Pop-Busui, Salim S. Hayek
Journal: Diabetes Care (2022)

OBJECTIVE Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. RESEARCH DESIGN AND METHODS We leveraged the International Study of Inflammation in COVID-19 (ISIC), a multicenter observational study of 2,044 patients hospitalized with COVID-19, to characterize the impact of DM on in-hospital outcomes and assess the contribution of inflammation and hyperglycemia to the risk attributed to DM. We measured biomarkers of inflammation collected at hospital admission and collected glucose levels and insulin data throughout hospitalization. The primary outcome was the composite of in-hospital death, need for mechanical ventilation, and need for renal replacement therapy. RESULTS Among participants (mean age 60 years, 58.2% males), those with DM (n = 686, 33.5%) had a significantly higher cumulative incidence of the primary outcome (37.8% vs. 28.6%) and higher levels of inflammatory biomarkers than those without DM. Among biomarkers, DM was only associated with higher soluble urokinase plasminogen activator receptor (suPAR) levels in multivariable analysis. Adjusting for suPAR levels abrogated the association between DM and the primary outcome (adjusted odds ratio 1.23 [95% CI 0.78, 1.37]). In mediation analysis, we estimated the proportion of the effect of DM on the primary outcome mediated by suPAR at 84.2%. Hyperglycemia and higher insulin doses were independent predictors of the primary outcome, with effect sizes unaffected by adjusting for suPAR levels. CONCLUSIONS Our findings suggest that the association between DM and outcomes in COVID-19 is largely mediated by hyperinflammation as assessed by suPAR levels, while the impact of hyperglycemia is independent of inflammation.
Risk-Adjusted, 30-Day Home Time After Transcatheter Aortic Valve Replacement as a Hospital-Level Performance Metric
Authors: Amgad Mentias, Neil Keshvani, Milind Y. Desai, Dharam J. Kumbhani, Mary Vaughan Sarrazin, Yubo Gao, Samir Kapadia, Eric D. Peterson, Michael Mack, Saket Girotra, Ambarish Pandey
Journal: Journal of the American College of Cardiology (2022)
Update: Impact of the Expanded AIDS Surveillance Case Definition for Adolescents and Adults on Case Reporting—United States, 1993
Journal: JAMA (1994)

During 1993, local, state, and territorial health departments reported 103,500 acquired immunodeficiency syndrome (AIDS) cases among persons aged > or = 13 years in the United States, an increase of 111% over the 49,016 reported in 1992 (Figure 1). This increase resulted from the expansion of the AIDS surveillance case definition in 1993*; in comparison, the number of cases based on the preexisting case definition decreased slightly. This report summarizes characteristics of persons reported with AIDS in 1993, compares these findings with data from 1992, and describes the impact of the change in the AIDS surveillance definition on AIDS case reporting.
Oral Contraceptive Use in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Absolute Cancer Risks and Benefits
Authors: Lieske H Schrijver, Thea M Mooij, Anouk Pijpe, Gabe S Sonke, Marian J E Mourits, Nadine Andrieu, Antonis C Antoniou, Douglas F Easton, Christoph Engel, David Goldgar, Esther M John, Karin Kast, Roger L Milne, Håkan Olsson, Kelly-Anne Phillips, Mary Beth Terry, John L Hopper, Flora E van Leeuwen, Matti A Rookus
Journal: JNCI Journal of the National Cancer Institute (2022)

To help BRCA1 and 2 mutation carriers make informed decisions regarding use of combined-type oral contraceptive preparation (COCP), absolute risk-benefit estimates are needed for COCP-associated cancer.
Re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316–7.
Authors: Joep J. de Jong, Ewan A. Gibb
Journal: European Urology (2022)
Initial results with the aegis vortex system, a new aspiro-atherectomy system with distal embolization protection, in the treatment of saphenous vein grafts B.F. Uretsky, W. Kussmaul, III, M. Buchbinder, B. George, G. Braden. University of Texas Medical Branch, Galveston, TX
Journal: Journal of the American College of Cardiology (2001)
Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group
Authors: Peter D. Stetson, Nadine J. McCleary, Travis Osterman, Kavitha Ramchandran, Amye Tevaarwerk, Tracy Wong, Jessica M. Sugalski, Wallace Akerley, Annette Mercurio, Finly J. Zachariah, Jonathan Yamzon, Robert C. Stillman, Peter E. Gabriel, Tricia Heinrichs, Kathleen Kerrigan, Shiven B. Patel, Scott M. Gilbert, Everett Weiss
Journal: Journal of the National Comprehensive Cancer Network (2022)

Background: Collecting, monitoring, and responding to patient-generated health data (PGHD) are associated with improved quality of life and patient satisfaction, and possibly with improved patient survival in oncology. However, the current state of adoption, types of PGHD collected, and degree of integration into electronic health records (EHRs) is unknown. Methods: The NCCN EHR Oncology Advisory Group formed a Patient-Reported Outcomes (PRO) Workgroup to perform an assessment and provide recommendations for cancer centers, researchers, and EHR vendors to advance the collection and use of PGHD in oncology. The issues were evaluated via a survey of NCCN Member Institutions. Questions were designed to assess the current state of PGHD collection, including how, what, and where PGHD are collected. Additionally, detailed questions about governance and data integration into EHRs were asked. Results: Of 28 Member Institutions surveyed, 23 responded. The collection and use of PGHD is widespread among NCCN Members Institutions (96%). Most centers (90%) embed at least some PGHD into the EHR, although challenges remain, as evidenced by 88% of respondents reporting the use of instruments not integrated. Forty-seven percent of respondents are leveraging PGHD for process automation and adherence to best evidence. Content type and integration touchpoints vary among the members, as well as governance maturity. Conclusions: The reported variability regarding PGHD suggests that it may not yet have reached its full potential for oncology care delivery. As the adoption of PGHD in oncology continues to expand, opportunities exist to enhance their utility. Among the recommendations for cancer centers is establishment of a governance process that includes patients. Researchers should consider determining which PGHD instruments confer the highest value. It is recommended that EHR vendors collaborate with cancer centers to develop solutions for the collection, interpretation, visualization, and use of PGHD.
Understanding and Improving Risk Assessment After Myocardial Infarction Using Automated Left Ventricular Shape Analysis
Authors: Jorge Corral Acero, Andreas Schuster, Ernesto Zacur, Torben Lange, Thomas Stiermaier, Sören J. Backhaus, Holger Thiele, Alfonso Bueno-Orovio, Pablo Lamata, Ingo Eitel, Vicente Grau
Journal: JACC. Cardiovascular imaging (2022)

Left ventricular ejection fraction (LVEF) and end-systolic volume (ESV) remain the main imaging biomarkers for post-acute myocardial infarction (AMI) risk stratification. However, they are limited to global systolic function and fail to capture functional and anatomical regional abnormalities, hindering their performance in risk stratification.This study aimed to identify novel 3-dimensional (3D) imaging end-systolic (ES) shape and contraction descriptors toward risk-related features and superior prognosis in AMI.A multicenter cohort of AMI survivors (n = 1,021; median age 63 years; 74.5% male) who underwent cardiac magnetic resonance (CMR) at a median of 3 days after infarction were considered for this study. The clinical endpoint was the 12-month rate of major adverse cardiac events (MACE; n = 73), consisting of all-cause death, reinfarction, and new congestive heart failure. A fully automated pipeline was developed to segment CMR images, build 3D statistical models of shape and contraction in AMI, and find the 3D patterns related to MACE occurrence.The novel ES shape markers proved to be superior to ESV (median cross-validated area under the receiver-operating characteristic curve 0.681 [IQR: 0.679-0.684] vs 0.600 [IQR: 0.598-0.602]; P < 0.001); and 3D contraction to LVEF (0.716 [IQR: 0.714-0.718] vs 0.681 [IQR: 0.679-0.684]; P < 0.001) in MACE occurrence prediction. They also contributed to a significant improvement in a multivariable setting including CMR markers, cardiovascular risk factors, and basic patient characteristics (0.747 [IQR: 0.745-0.749]; P < 0.001). Based on these novel 3D descriptors, 3 impairments caused by AMI were identified: global, anterior, and basal, the latter being the most complementary signature to already known predictors.The quantification of 3D differences in ES shape and contraction, enabled by a fully automated pipeline, improves post-AMI risk prediction and identifies shape and contraction patterns related to MACE occurrence.
Effects of angiotensin II receptor blockade, angiotensin-converting enzyme inhibition, and their combination on postinfarction ventricular remodeling Sunil Mankad, Nathaniel Reichek, Deepak Singh, Walter J. Rogers, Christopher M. Kramer. Allegheny General Hospital, Pittsburg, PA , University of Virginia Health System, Charlottesville, VA
Journal: Journal of the American College of Cardiology (2001)